题名 | PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer |
作者 | Glaviano, Antonino1; Foo, Aaron S. C.2; Lam, Hiu Y.3,4; Yap, Kenneth C. H.3,4; Jacot, William5; Jones, Robert H.6; Eng, Huiyan2,3; Nair, Madhumathy G.7; Makvandi, Pooyan8; Geoerger, Birgit9; Kulke, Matthew H.10; Baird, Richard D.11; Prabhu, Jyothi S.7; Carbone, Daniela1; Pecoraro, Camilla1; Teh, Daniel B. L.12; Sethi, Gautam2,3; Cavalieri, Vincenzo1; Lin, Kevin H.13; Javidi-Sharifi, Nathalie R.13; Toska, Eneda14; Davids, Matthew S.13; Brown, Jennifer R.13; Diana, Patrizia1; Stebbing, Justin15; Fruman, David A.16; Kumar, Alan P.2,3
|
发表日期 | 2023-08-18 |
发表期刊 | Molecular cancer 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Journal Article ; Review |
关键词 | AKT inhibitors ATP-competitive mTOR inhibitors Allosteric mTOR inhibitors Bi-steric mTOR inhibitors Cancer Dual PI3K/mTOR inhibitors Isoform-specific PI3K inhibitors PDK1 inhibitors PI3K/AKT/mTORC pathway Pan PI3K inhibitors |
其他关键词 | RENAL-CELL CARCINOMA ; FOXO TRANSCRIPTION FACTORS ; ADVANCED BREAST-CANCER ; PHASE-I TRIAL ; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR ; NONFUNCTIONAL NEUROENDOCRINE TUMORS ; CHRONIC LYMPHOCYTIC-LEUKEMIA ; INTRAVENOUS PI3K INHIBITOR ; PROTEIN-COUPLED RECEPTORS ; HEPATOCYTE GROWTH-FACTOR |
摘要 | The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer development. The PAM axis is the most frequently activated signaling pathway in human cancer and is often implicated in resistance to anticancer therapies. Dysfunction of components of this pathway such as hyperactivity of PI3K, loss of function of PTEN, and gain-of-function of AKT, are notorious drivers of treatment resistance and disease progression in cancer. In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR inhibitors as monotherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy for overcoming treatment resistance. Finally, the major mechanisms of resistance to PAM signaling targeted therapies, including PAM signaling in immunology and immunotherapies are also discussed. |
资助项目 | ingapore Ministry of Education [MOE-T2EP30120-0016] |
出版者 | BMC |
ISSN | 1476-4598 |
EISSN | 1476-4598 |
卷号 | 22期号:1 |
DOI | 10.1186/s12943-023-01827-6 |
页数 | 37 |
WOS类目 | Biochemistry & Molecular Biology ; Oncology |
WOS研究方向 | Biochemistry & Molecular Biology ; Oncology |
WOS记录号 | WOS:001050375700001 |
收录类别 | PUBMED ; SCIE ; SCOPUS |
URL | 查看原文 |
PubMed ID | 37596643 |
SCOPUSEID | 2-s2.0-85168348160 |
ESI热点论文 | 2024-05 ; 2024-07 ; 2024-09 ; 2024-11 |
ESI高被引论文 | 2024-03 ; 2024-05 ; 2024-07 ; 2024-09 |
通讯作者地址 | [Kumar, Alan P.]Department of Surgery,National University Hospital Singapore,National University of Singapore,Singapore,Singapore |
Scopus学科分类 | Molecular Medicine;Oncology;Cancer Research |
TOP期刊 | TOP期刊 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/182457 |
专题 | 其他_温州医科大学附属衢州医院 |
通讯作者 | Kumar, Alan P. |
作者单位 | 1.Department of Biological,Chemical and Pharmaceutical Sciences and Technologies,University of Palermo,Palermo,90123,Italy; 2.Department of Surgery,National University Hospital Singapore,National University of Singapore,Singapore,Singapore; 3.Department of Pharmacology,Yong Loo Lin School of Medicine,National University of Singapore,Singapore,117600,Singapore; 4.NUS Centre for Cancer Research (N2CR),Yong Loo Lin School of Medicine,National University of Singapore,Singapore,119077,Singapore; 5.Department of Medical Oncology,Institut du Cancer de Montpellier,Inserm U1194,Montpellier University,Montpellier,France; 6.Cardiff University and Velindre Cancer Centre,Museum Avenue,Cardiff,CF10 3AX,United Kingdom; 7.Division of Molecular Medicine,St. John’s Research Institute,St. John’s Medical College,Bangalore,560034,India; 8.The Quzhou Affiliated Hospital of Wenzhou Medical University,Quzhou People’s Hospital,Zhejiang,Quzhou,324000,China; 9.Department of Pediatric and Adolescent Oncology,Gustave Roussy Cancer Center,Inserm U1015,Université Paris-Saclay,Paris,France; 10.Section of Hematology and Medical Oncology,Boston University and Boston Medical Center,Boston,United States; 11.Cancer Research UK Cambridge Centre,Hills Road,Cambridge,CB2 0QQ,United Kingdom; 12.Departments of Ophthalmology and Anatomy,Yong Loo Lin School of Medicine,National University of Singapore,and Neurobiology Programme,National University of Singapore,Singapore,Singapore; 13.Dana-Farber Cancer Institute,Harvard Medical School,Boston,United States; 14.Department of Biochemistry and Molecular Biology,Johns Hopkins School of Public Health,Baltimore,United States; 15.Division of Cancer,Imperial College London,Hammersmith Campus, Du Cane Road,London,W12 0NN,United Kingdom; 16.Department of Molecular Biology and Biochemistry,University of California,216 Sprague Hall,Irvine,United States |
推荐引用方式 GB/T 7714 | Glaviano, Antonino,Foo, Aaron S. C.,Lam, Hiu Y.,et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer[J]. Molecular cancer,2023,22(1). |
APA | Glaviano, Antonino., Foo, Aaron S. C.., Lam, Hiu Y.., Yap, Kenneth C. H.., Jacot, William., ... & Kumar, Alan P.. (2023). PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular cancer, 22(1). |
MLA | Glaviano, Antonino,et al."PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer".Molecular cancer 22.1(2023). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论